Why Is Dupixent So Hard to Find? [Explained for 2026]

If you've ever tried to fill a Dupixent prescription, you know the process feels anything but straightforward. You leave your dermatologist's office with a prescription in hand — and then the waiting game begins. Prior authorization reviews, specialty pharmacy transfers, insurance appeals. Many patients wait weeks before their first dose arrives.

So what's actually going on? Is Dupixent in short supply? Is there a manufacturing shortage? The short answer: no — but the access problem is real, and understanding it is the first step toward solving it.

Is Dupixent in an FDA Drug Shortage?

No. As of 2026, Dupixent (dupilumab) is not listed on the FDA's official drug shortage database. Sanofi and Regeneron are actively manufacturing and distributing it. The drug is available — the challenge is getting it from the manufacturer to you.

This is what experts sometimes call a "practical access barrier" — the drug exists, but the system surrounding it creates significant friction for patients. The barriers fall into four main categories: specialty pharmacy distribution, prior authorization requirements, high cost, and insurance formulary decisions.

Reason #1: Dupixent Is Only Available Through Specialty Pharmacies

Unlike most medications, Dupixent cannot be filled at your neighborhood pharmacy. It is exclusively dispensed through specialty pharmacies — facilities equipped to handle complex biologics that require refrigerated shipping, detailed patient counseling, and coordinated care management.

This means that even after your doctor sends the prescription, it must be routed to a specialty pharmacy (often CVS Specialty, Walgreens Specialty, or Accredo). The specialty pharmacy then confirms insurance, obtains prior authorization, and coordinates delivery — all before you receive your medication. Each step in this chain takes time and can hit a snag.

Reason #2: Prior Authorization Is Almost Always Required

Prior authorization (PA) is the insurance process by which your plan reviews whether Dupixent is medically necessary for you before they agree to cover it. And with Dupixent — a specialty biologic with a list price of over $4,193 per carton in 2026 — nearly every insurance plan requires PA.

Prior authorization for Dupixent typically requires:

Documentation of your diagnosis (e.g., moderate-to-severe atopic dermatitis, asthma, CRSwNP)

Evidence that you tried and failed (or have a contraindication to) other first-line therapies

A prescription from a specialist (dermatologist, allergist, pulmonologist, etc.)

A letter of medical necessity from your prescriber

Even when all the documentation is in order, insurance reviewers can take days or weeks. Initial denials are common, and appeals — while often successful — add more time to an already lengthy process.

Reason #3: Step Therapy Adds More Hurdles

Many insurance plans use step therapy — sometimes called "fail first" — which requires patients to try and fail on cheaper medications before approving a more expensive drug like Dupixent. For atopic dermatitis patients, this might mean proving that topical corticosteroids, calcineurin inhibitors, or even phototherapy didn't work well enough.

For asthma patients, step therapy might require documented failure on high-dose inhaled corticosteroids plus a long-acting beta-agonist before Dupixent is approved. For CRSwNP patients, prior intranasal corticosteroid trials and sometimes surgery may be required. These step therapy requirements mean some patients wait months — or even a full year — before they can access Dupixent.

Reason #4: The Cost Creates Real Barriers Without Insurance

Dupixent has a list price of approximately $4,193 per carton (2 injections) as of January 2026 — which translates to roughly $50,000 per year at full list price. The retail price at pharmacies can run even higher, often around $5,500 per carton. Very few patients pay this amount, but for those without insurance or with plans that exclude Dupixent from their formulary, cost alone can make the drug essentially inaccessible.

Manufacturer savings programs like the DUPIXENT MyWay Copay Card can bring the cost down to as little as $0 per fill for eligible patients with commercial insurance. For uninsured patients, the DUPIXENT MyWay Patient Assistance Program may provide the medication at no cost to qualifying patients based on income. But navigating these programs takes time, effort, and often the help of a specialist's office staff.

Reason #5: Formulary Placement and Insurance Denials

Even when prior authorization is granted, Dupixent is typically placed on a specialty drug tier — the highest and most expensive tier on most formularies. Some plans restrict it to specific specialty pharmacies, limit quantities, or require periodic re-authorization. When insurance plans update their formularies each January, patients who were previously covered may suddenly face higher copays or a new PA requirement.

Insurance denials for Dupixent commonly happen when:

The plan doesn't consider the diagnosis severe enough to meet criteria

Step therapy requirements haven't been documented as completed

The prescribing physician is a generalist (some plans require specialist prescriptions)

The patient is on another biologic simultaneously

Why Dupixent's Multi-Indication Status Makes Access Harder

Dupixent now has 9 FDA-approved indications — from eczema and asthma to COPD, eosinophilic esophagitis, and most recently chronic spontaneous urticaria in children as young as 2. This broad approval means it's being prescribed by dermatologists, allergists, pulmonologists, otolaryngologists, and gastroenterologists. Each specialty has different insurance PA requirements, different step therapy protocols, and different specialty pharmacy routing.

The result: even for a drug that is not in a manufacturing shortage, the complexity of the coverage landscape creates access barriers that feel very much like a shortage from the patient's perspective.

What Can You Do Right Now?

If you're struggling to access Dupixent, here are concrete steps that help:

Ask your prescriber's office to submit PA paperwork the same day as your appointment — delays often start here.

Enroll in DUPIXENT MyWay at 1-844-387-4936 for insurance navigation help and potential copay assistance.

If denied, appeal immediately — most insurance denials for Dupixent can be overturned with additional documentation.

Ask your prescriber about bridge supplies — Sanofi sometimes provides starter doses while PA is pending.

Use medfinder to find specialty pharmacies in your area that carry Dupixent — so you're not scrambling once your authorization comes through.

The Bottom Line

Dupixent is not in a manufacturing shortage, but the specialty pharmacy system, prior authorization requirements, step therapy policies, and high costs create very real obstacles. Understanding which obstacle is blocking you is the first step toward breaking through it. For more practical guidance on locating a pharmacy with Dupixent in stock and navigating the process, see our guide on how to find Dupixent in stock near you.